+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New Chemical Entities Market - Global Forecast 2026-2032- Product Image
New Chemical Entities Market - Global Forecast 2026-2032- Product Image
Sale

New Chemical Entities Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6277802
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Chemical Entities: Executive Summary

New chemical entities (NCEs) are active pharmaceutical ingredients with structures not previously approved for therapeutic use. Their development combines discovery science, translational research, clinical evaluation, regulatory review, manufacturing readiness, and post-approval evidence generation. The field is shaped by advances in molecular design, biomarker science, precision medicine, and increasingly complex safety and manufacturing requirements.

Development Is Becoming More Data-Intensive and Collaborative

NCE development is shifting toward target validation supported by human genetics, high-throughput screening, structural biology, and translational biomarkers. Regulatory pathways increasingly emphasize benefit-risk evidence, clinically meaningful endpoints, and lifecycle monitoring. At the same time, development programs are becoming more collaborative, linking academic laboratories, biotechnology innovators, contract research organizations, manufacturers, patient groups, and public agencies. These shifts increase the importance of reproducible data standards, early manufacturability assessment, and integrated clinical-development planning.

Artificial Intelligence Is Compressing Discovery and Decision Cycles

Artificial intelligence is being applied to target identification, molecular generation, virtual screening, property prediction, biomarker discovery, clinical-trial design, and safety-signal analysis. Its cumulative impact depends less on model sophistication alone than on the quality, provenance, interoperability, and governance of the underlying data. AI can prioritize experiments and reduce avoidable iteration, but laboratory validation, clinical judgment, explainability, privacy protection, and regulatory accountability remain essential. Leaders should treat AI as a decision-support capability embedded in controlled workflows rather than as a substitute for experimental evidence.

Regional Ecosystems Differ in Science, Regulation, and Manufacturing

North America combines deep biomedical research capacity, sophisticated capital and trial infrastructure, and mature regulatory institutions. Europe benefits from strong academic networks and coordinated regulatory mechanisms, while national reimbursement and evidence requirements remain important. Asia-Pacific is expanding its discovery, clinical, and manufacturing capabilities, with substantial variation across jurisdictions. Latin America offers diverse patient populations and growing research capacity, but operational execution and regulatory harmonization can vary. The Middle East is strengthening innovation, healthcare, and investment platforms, whereas Africa presents important unmet-need opportunities alongside infrastructure, access, and trial-capacity constraints. Across all regions, local evidence expectations, technology transfer, supply resilience, and equitable access are central considerations.

Economic and Security Blocs Shape Collaboration and Access

ASEAN countries offer a connected but heterogeneous environment in which regulatory alignment and cross-border trial execution remain important. BRICS members span major scientific, manufacturing, and patient populations, while differences in regulatory systems and health financing require tailored strategies. The European Union provides a broad framework for coordinated oversight alongside national implementation differences. G7 economies contribute advanced research, regulatory, and manufacturing capabilities, with increasing attention to resilience and responsible innovation. GCC states are investing in healthcare modernization and life-sciences infrastructure. NATO members also operate within a broader context of supply-chain security, public-health preparedness, and strategic technology governance.

Country Priorities Reflect Distinct Scientific and Regulatory Contexts

Australia supports early-phase research through established institutions and a diverse clinical environment. Brazil and Mexico provide significant patient populations and growing research capabilities, while local regulatory and operational expertise is essential. Canada combines strong academic science with an integrated healthcare context. China, India, Japan, and South Korea have substantial discovery, clinical, manufacturing, and technology capabilities, though regulatory pathways and data requirements differ. France, Germany, Italy, Spain, and the United Kingdom offer sophisticated research and healthcare systems with distinct national evidence and access processes. Russia’s scientific and healthcare environment must be assessed alongside regulatory, operational, and geopolitical constraints. In the United States, advanced research, trial infrastructure, and regulatory experience support complex NCE programs, while payer evidence and commercialization planning remain important.

Prioritize Translational Proof, Resilient Operations, and Responsible AI

Industry leaders should establish target-validation gates that combine human biology, disease relevance, biomarker strategy, and a credible therapeutic index. Development teams should assess formulation, analytical methods, scale-up, intellectual-property position, and supply-chain dependencies before major clinical commitments. Regional plans should account for regulatory divergence, local trial capabilities, health-system evidence needs, and access considerations. Organizations adopting AI should implement documented validation, bias testing, model monitoring, data-governance controls, and human oversight. Partnerships should be structured around clearly defined evidence milestones, decision rights, technology-transfer provisions, and quality responsibilities.

Methodology: Evidence-Based Synthesis of the NCE Development Environment

This executive summary uses the supplied market scope-new chemical entities-and synthesizes established, publicly documented characteristics of pharmaceutical discovery, development, regulation, manufacturing, clinical research, and healthcare access. The analysis is organized across technology, operating-model, regional, group, and country dimensions. It emphasizes verifiable structural trends rather than numerical market claims, and it distinguishes broad ecosystem observations from jurisdiction-specific considerations. No market estimates, forecasts, market shares, or company-specific claims are used.

Successful NCE Programs Will Integrate Science, Evidence, and Execution

The NCE landscape is being reshaped by better biological insight, data-intensive experimentation, AI-enabled prioritization, stricter evidence expectations, and the need for resilient global operations. Progress will depend on connecting discovery decisions with clinical translation, scalable manufacturing, regulatory strategy, and equitable access from the outset. Organizations that combine rigorous validation with disciplined technology governance and regionally informed execution will be better positioned to convert promising chemistry into durable therapeutic value.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. New Chemical Entities Market, by Therapeutic Area
7.1. Introduction
7.2. Cardiovascular
7.3. Central Nervous System
7.4. Immunology & Inflammation
7.5. Infectious Diseases
7.6. Metabolic Disorders
7.7. Oncology
7.8. Respiratory
8. New Chemical Entities Market, by Regulatory Approval Status
8.1. Introduction
8.2. Approved
8.3. Clinical Development
8.4. Preclinical/Discovery
8.5. Under Review
9. New Chemical Entities Market, by Route Of Administration
9.1. Introduction
9.2. Inhalation
9.3. Injectable
9.4. Nasal
9.5. Oral
9.6. Topical
9.7. Transdermal
10. New Chemical Entities Market, by Dosage Form
10.1. Introduction
10.2. Capsules
10.3. Inhalation Devices
10.4. Injectables
10.5. Liquid Oral
10.6. Tablets
10.7. Topicals
10.8. Transdermal Patches
11. New Chemical Entities Market, by Patent Protection Status
11.1. Introduction
11.2. Exclusivity
11.3. Patent Challenged
11.4. Patent Expired
11.5. Patent Protected
12. New Chemical Entities Market, by Mode Of Action
12.1. Introduction
12.2. Enzyme Inhibitors
12.3. Hormones & Analogues
12.4. Ion Channel Modulators
12.5. Kinase Inhibitors
12.6. Receptor Antagonists & Agonists
13. New Chemical Entities Market, by Therapeutic Modality
13.1. Introduction
13.2. Conjugates
13.3. Oligonucleotides
13.4. Peptides
13.5. Small Molecules
14. New Chemical Entities Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. New Chemical Entities Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. New Chemical Entities Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. AbbVie Inc
18.2. Amgen Inc
18.3. AstraZeneca PLC
18.4. Biogen Inc
18.5. Boehringer Ingelheim International GmbH
18.6. Bristol Myers Squibb Company
18.7. Daiichi Sankyo Company Limited
18.8. Eli Lilly and Company
18.9. Gilead Sciences Inc
18.10. GlaxoSmithKline PLC
18.11. Incyte Corporation
18.12. Jiangsu Hengrui Pharmaceuticals Co Ltd
18.13. Johnson & Johnson
18.14. Merck & Co Inc
18.15. Moderna Inc
18.16. Novartis AG
18.17. Novo Nordisk AS
18.18. Otsuka Holdings Co Ltd
18.19. Pfizer Inc
18.20. Regeneron Pharmaceuticals Inc
18.21. Roche Holding AG
18.22. Sanofi SA
18.23. Takeda Pharmaceutical Company Limited
18.24. UCB SA
18.25. Vertex Pharmaceuticals Incorporated
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global New Chemical Entities Market, Years Considered for the Study
FIGURE 2. Global New Chemical Entities Market, Research Design
FIGURE 3. Global New Chemical Entities Market, Research Framework
FIGURE 4. Global New Chemical Entities Market, Data Triangulation
FIGURE 5. Global New Chemical Entities Market Size, 2017-2032 (USD Million)
FIGURE 6. Global New Chemical Entities Market Size, by Therapeutic Area, 2025 vs 2032 (%)
FIGURE 7. Global New Chemical Entities Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global New Chemical Entities Market Size, by Regulatory Approval Status, 2025 vs 2032 (%)
FIGURE 9. Global New Chemical Entities Market Size, by Regulatory Approval Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global New Chemical Entities Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global New Chemical Entities Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global New Chemical Entities Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 13. Global New Chemical Entities Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global New Chemical Entities Market Size, by Patent Protection Status, 2025 vs 2032 (%)
FIGURE 15. Global New Chemical Entities Market Size, by Patent Protection Status, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global New Chemical Entities Market Size, by Mode Of Action, 2025 vs 2032 (%)
FIGURE 17. Global New Chemical Entities Market Size, by Mode Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global New Chemical Entities Market Size, by Therapeutic Modality, 2025 vs 2032 (%)
FIGURE 19. Global New Chemical Entities Market Size, by Therapeutic Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global New Chemical Entities Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global New Chemical Entities Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global New Chemical Entities Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global New Chemical Entities Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global New Chemical Entities Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global New Chemical Entities Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global New Chemical Entities Market Segmentation & Coverage
TABLE 2. Global New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 3. Global New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 4. Global Cardiovascular Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cardiovascular Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cardiovascular Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Central Nervous System Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Central Nervous System Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Central Nervous System Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Immunology & Inflammation Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Immunology & Inflammation Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Immunology & Inflammation Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Respiratory Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Respiratory Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Respiratory Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 26. Global Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Preclinical/Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Preclinical/Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Preclinical/Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Under Review Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Under Review Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Under Review Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 39. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Topical Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Topical Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Topical Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 58. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Inhalation Devices Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Inhalation Devices Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Inhalation Devices Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Injectables Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Injectables Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Injectables Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Liquid Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Liquid Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Liquid Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Topicals Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Topicals Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Topicals Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Transdermal Patches Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Transdermal Patches Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Transdermal Patches Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 80. Global Exclusivity Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Exclusivity Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Exclusivity Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Patent Challenged Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Patent Challenged Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Patent Challenged Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Patent Expired Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Patent Expired Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Patent Expired Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Patent Protected Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Patent Protected Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Patent Protected Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 93. Global Enzyme Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Enzyme Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Enzyme Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Hormones & Analogues Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Hormones & Analogues Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Hormones & Analogues Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Ion Channel Modulators Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Ion Channel Modulators Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Ion Channel Modulators Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Kinase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 103. Global Kinase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. Global Kinase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 105. Global Receptor Antagonists & Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Receptor Antagonists & Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Receptor Antagonists & Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 109. Global Conjugates Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Conjugates Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Conjugates Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global Small Molecules Market Size, by Region, 2017-2032 (USD Million)
TABLE 119. Global Small Molecules Market Size, by Group, 2017-2032 (USD Million)
TABLE 120. Global Small Molecules Market Size, by Country, 2017-2032 (USD Million)
TABLE 121. Global New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 128. Asia-Pacific New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 129. Asia-Pacific New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 130. North America New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. North America New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 132. North America New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 133. North America New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. North America New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 135. North America New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 136. North America New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 137. North America New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 138. Latin America New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 139. Latin America New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 140. Latin America New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 141. Latin America New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 142. Latin America New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 143. Latin America New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 144. Latin America New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 145. Latin America New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 146. Europe New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Europe New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 148. Europe New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 149. Europe New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 150. Europe New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 151. Europe New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 152. Europe New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 153. Europe New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 154. Middle East New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Middle East New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 156. Middle East New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 157. Middle East New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. Middle East New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 159. Middle East New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 160. Middle East New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 161. Middle East New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 162. Africa New Chemical Entities Market Size, by Region, 2017-2032 (USD Million)
TABLE 163. Africa New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 164. Africa New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 165. Africa New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 166. Africa New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 167. Africa New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 168. Africa New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 169. Africa New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 170. Global New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 171. ASEAN New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. ASEAN New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 173. ASEAN New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 174. ASEAN New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 175. ASEAN New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 176. ASEAN New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 177. ASEAN New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 178. ASEAN New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 179. GCC New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 180. GCC New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 181. GCC New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 182. GCC New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 183. GCC New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 184. GCC New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 185. GCC New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 186. GCC New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 187. European Union New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 188. European Union New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 189. European Union New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 190. European Union New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. European Union New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 192. European Union New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 193. European Union New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 194. European Union New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 195. BRICS New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 196. BRICS New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 197. BRICS New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 198. BRICS New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 199. BRICS New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 200. BRICS New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 201. BRICS New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 202. BRICS New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 203. G7 New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 204. G7 New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 205. G7 New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 206. G7 New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 207. G7 New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 208. G7 New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 209. G7 New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 210. G7 New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 211. NATO New Chemical Entities Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. NATO New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 213. NATO New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 214. NATO New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 215. NATO New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 216. NATO New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 217. NATO New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 218. NATO New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 219. Global New Chemical Entities Market Size, by Country, 2017-2032 (USD Million)
TABLE 220. United States New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 221. United States New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 222. United States New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 223. United States New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 224. United States New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 225. United States New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 226. United States New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 227. United States New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 228. Canada New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 229. Canada New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 230. Canada New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 231. Canada New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 232. Canada New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 233. Canada New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 234. Canada New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 235. Canada New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 236. Mexico New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 237. Mexico New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 238. Mexico New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 239. Mexico New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. Mexico New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 241. Mexico New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 242. Mexico New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 243. Mexico New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 244. Brazil New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 245. Brazil New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 246. Brazil New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 247. Brazil New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 248. Brazil New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 249. Brazil New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 250. Brazil New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 251. Brazil New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 252. United Kingdom New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 253. United Kingdom New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 254. United Kingdom New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 255. United Kingdom New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 256. United Kingdom New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 257. United Kingdom New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 258. United Kingdom New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 259. United Kingdom New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 260. Germany New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 261. Germany New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 262. Germany New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 263. Germany New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 264. Germany New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 265. Germany New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 266. Germany New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 267. Germany New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 268. France New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 269. France New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 270. France New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 271. France New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 272. France New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 273. France New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 274. France New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 275. France New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 276. Russia New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 277. Russia New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 278. Russia New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 279. Russia New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 280. Russia New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 281. Russia New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 282. Russia New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 283. Russia New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 284. Italy New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 285. Italy New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 286. Italy New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 287. Italy New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 288. Italy New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 289. Italy New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 290. Italy New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 291. Italy New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 292. Spain New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 293. Spain New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 294. Spain New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 295. Spain New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 296. Spain New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 297. Spain New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 298. Spain New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 299. Spain New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 300. China New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 301. China New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 302. China New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 303. China New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 304. China New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 305. China New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 306. China New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 307. China New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 308. India New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 309. India New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 310. India New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 311. India New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 312. India New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 313. India New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 314. India New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 315. India New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 316. Japan New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 317. Japan New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 318. Japan New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 319. Japan New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 320. Japan New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 321. Japan New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 322. Japan New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 323. Japan New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 324. Australia New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 325. Australia New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 326. Australia New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 327. Australia New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 328. Australia New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 329. Australia New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 330. Australia New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 331. Australia New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 332. South Korea New Chemical Entities Market Size, 2017-2032 (USD Million)
TABLE 333. South Korea New Chemical Entities Market Size, by Therapeutic Area, 2017-2032 (USD Million)
TABLE 334. South Korea New Chemical Entities Market Size, by Regulatory Approval Status, 2017-2032 (USD Million)
TABLE 335. South Korea New Chemical Entities Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 336. South Korea New Chemical Entities Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 337. South Korea New Chemical Entities Market Size, by Patent Protection Status, 2017-2032 (USD Million)
TABLE 338. South Korea New Chemical Entities Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 339. South Korea New Chemical Entities Market Size, by Therapeutic Modality, 2017-2032 (USD Million)
TABLE 340. Global New Chemical Entities Market Share, by Key Player, 2025
TABLE 341. Global New Chemical Entities Market, Key Experts

Companies Mentioned

  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca PLC
  • Biogen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Gilead Sciences Inc
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Jiangsu Hengrui Pharmaceuticals Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • Moderna Inc
  • Novartis AG
  • Novo Nordisk AS
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

New Chemical Entities CDMO Market - Global Forecast 2026-2032 - Product Image

New Chemical Entities CDMO Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Chloroethyl Chloroformate Market - Global Forecast 2026-2032 - Product Image

Chloroethyl Chloroformate Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Chlorogold Market - Global Forecast 2026-2032 - Product Image

Chlorogold Market - Global Forecast 2026-2032

  • Report
  • 186 Pages
  • Global
From
Long-acting Polypeptide Fatty Acid Side Chain Market - Global Forecast 2026-2032 - Product Image

Long-acting Polypeptide Fatty Acid Side Chain Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
2-Chloro-8-Cyclopentyl-5-Methylpyrido[2,3-D]Pyrimidin-7-One Market - Global Forecast 2026-2032 - Product Image

2-Chloro-8-Cyclopentyl-5-Methylpyrido[2,3-D]Pyrimidin-7-One Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.